Abstract: A database system may use asymmetric hardware for analytics nodes. In some embodiments, a database system includes a replica set comprising a plurality of base nodes and at least one analytics node. The analytics nodes may have asymmetric hardware respective to the base nodes. The base nodes may include a primary node and two secondary nodes. The primary node may be configured to accept writes and propagate the writes to secondary nodes and may also propagate writes to analytics nodes. Secondary nodes may replicate writes and accept reads. Analytics nodes may perform data analysis operations. Analytics nodes may have a first instance size different than a second instance size of the base nodes.

Abstract: A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.

Abstract: The present invention is related to compositions comprising clarified limulus amebocyte lysate (LAL), wherein the LAL is substantially free of coagulogen and methods of making such compositions. The invention further relates to a method of detecting an endotoxin in a sample using a chromogenic assay, the method comprising: (a) contacting the sample with a reagent comprising clarified LAL and a chromogenic substrate; and (b) measuring a chromogenic effect resulting from a change in the chromogenic substrate in the presence of endotoxin in the sample, wherein the LAL is substantially free of coagulogen. The invention also relates to kits comprising clarified LAL substantially free of coagulogen, and methods of making such.

Abstract: The present invention is related to compositions comprising clarified limulus amebocyte lysate (LAL), wherein the LAL is substantially free of coagulogen and methods of making such compositions. The invention further relates to a method of detecting an endotoxin in a sample using a chromogenic assay, the method comprising: (a) contacting the sample with a reagent comprising clarified LAL and a chromogenic substrate; and (b) measuring a chromogenic effect resulting from a change in the chromogenic substrate in the presence of endotoxin in the sample, wherein the LAL is substantially free of coagulogen. The invention also relates to kits comprising clarified LAL substantially free of coagulogen, and methods of making such.

Abstract: A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.

Abstract: The present invention is related to compositions comprising clarified limulus amebocyte lysate (LAL), wherein the LAL is substantially free of coagulogen and methods of making such compositions. The invention further relates to a method of detecting an endotoxin in a sample using a chromogenic assay, the method comprising: (a) contacting the sample with a reagent comprising clarified LAL and a chromogenic substrate; and (b) measuring a chromogenic effect resulting from a change in the chromogenic substrate in the presence of endotoxin in the sample, wherein the LAL is substantially free of coagulogen. The invention also relates to kits comprising clarified LAL substantially free of coagulogen, and methods of making such.

Abstract: A process for coating a glass article of manufacture may include providing a glass article at an initial temperature of above about 105° C., and depositing a coating onto a surface of said glass article. The coating may include an adhesion promoter and a compounded polymer that includes a copolymer of an ?-olefin and an ?,?-unsaturated carboxylic acid and a wax. The process may include heating said glass article to a temperature above said initial temperature sufficient to promote adhesion of said coating to said glass article. Glass articles having the coating adhered to the glass article are also described.

Abstract: A manufacturing method for container having an opening and a bottom on which an artificial creature is disposed includes the following steps: (a) forming an artificial creature integrated with a base by plastic injection molding; (b) providing a injection mold comprising a male mold and a female mold comprising a cavity corresponding to the artificial creature; (c) positioning the artificial creature and the base to the male mold; and (d) matching the male mold and female mold to form paths between the male mold and female mold and between the base and the female mold to allow molten plastic flow therethrough so as to form the container in such a manner that the bottom of the container encloses the base so as to position the artificial animal on the bottom of the container.

Abstract: A manufacturing method for container having an opening and a bottom on which an artificial creature is disposed includes the following steps: (a) forming an artificial creature integrated with a base by plastic injection molding; (b) providing a injection mold comprising a male mold and a female mold comprising a cavity corresponding to the artificial creature; (c) positioning the artificial creature and the base to the male mold; and (d) matching the male mold and female mold to form paths between the male mold and female mold and between the base and the female mold to allow molten plastic flow therethrough so as to form the container in such a manner that the bottom of the container encloses the base so as to position the artificial animal on the bottom of the container.

Abstract: The present invention provides a treating unit of activated sludge for wastewater treatment and a treating apparatus having the same. The treating unit is constructed by a cage-shaped supporting structure which defines an interior space for containing the microbial cell therein. The present invention provides a measure for simultaneous removal of organics and nitrogen compounds from the wastewater under a condition of controlled aeration, and makes the configuration of treating apparatus as well as the treating process more simplified. It is also an alternative to replace the traditional A2O process. According to the present invention, the design of sludge return, which is essential for the conventional activated sludge treatment, is not needed. Moreover, the present invention is compatible with the conventional activated sludge treatment process and is advantageous in its short start-up period during which a stable operation is achievable.

Abstract: The present invention provides a treating unit of activated sludge for wastewater treatment and a treating apparatus having the same. The treating unit is constructed by a cage-shaped supporting structure which defines an interior space for containing the microbial cell therein. The present invention provides a measure for simultaneous removal of organics and nitrogen compounds from the wastewater under a condition of controlled aeration, and makes the configuration of treating apparatus as well as the treating process more simplified. It is also an alternative to replace the traditional A2O process. According to the present invention, the design of sludge return, which is essential for the conventional activated sludge treatment, is not needed. Moreover, the present invention is compatible with the conventional activated sludge treatment process and is advantageous in its short start-up period during which a stable operation is achievable.